Ingelheim am Rhein, Germany and Geneva, Switzerland – Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunization platform.
SYDNEY Australia – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California.
New York, US and Vienna, Austria - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that its Investigational New Drug (IND) Application for a Phase 1/2 clinical trial of HB-201, a TheraT®*-based immunotherapy, for the treatment of Human Papilloma Virus (HPV)-positive cancers is now effective following the clearance by the U.S. Food and Drug Administration (FDA).
MELBOURNE Australia – Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, today announced the start of a Phase 1b trial of its second targeted anti-cancer drug PTX-100 in Australia.
Cambridge, UK – Healx, the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announces the appointment of Dr Neil Thompson, PhD, as Chief Scientific Officer (CSO).
Cambridge, UK - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces the outcome of its strategic review following the appointment of Dr Tom Oakley as CEO in April 2019. The Board is also pleased to provide a trading update on the year ended 31 May 2019.
SYDNEY, Australia - Recce Pharmaceuticals Ltd (ASX: RCE, “Recce” or the “Company”), the company developing a new class of synthetic antibiotics, today announced that Dr John Prendergast has been appointed to Independent Chair with founder Dr Graham Melrose stepping back from the role of Executive Chair to Executive Director and Chief Research Officer. In addition, the Company’s Principle Chemist, Dr Justin Ward, has been appointed to the Board as Executive Director. These changes are effective today.
SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
Tuebingen, Germany and Houston, Texas – Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).
Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation in Life sciences and associated industries, announces the launch of Sport & Performance Capital™, a new fund dedicated to supporting innovation in the sport and wellness industries. With a final target of €80 million, the venture fund will invest in startup companies and growing SMEs furthering physical activity to help promote health and physical fitness.
Manchester, UK – 4 July 2019 - SkinBioTherapeutics plc (AIM: SBTX or the “Company”), a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.
Ghent, Belgium, and Dresden, Germany - Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR).
Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in life science microbiome investment, is pleased to provide an update on its Health for Life investments for the period March 2019 to June 2019 (Note: June 27 is now marked The World Microbiome Day).
Hadfield, UK – RevoluGen Limited announced today a global distribution agreement for its Fire Monkey / Fire Flower product with Merck. The Fire Monkey / Fire Flower product is a kit that can be used to perform either the Fire Monkey purification of DNA for long-read sequencing applications, utilizing its reliable, rapid, user friendly protocol, or to perform the Fire Flower DNA size selection protocol.
Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.
Ascot, UK – RevoluGen, a privately held scientific company specialising in the development and commercialisation of nucleic acid isolation and purification products, today announces the appointment of Stefano Giolito as Chief Marketing Officer, effective immediately.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has been granted marketing authorisations for Melatonin 1mg/ml Oral Solution and Melatonin 3mg Film-Coated Tablets by the Medicines and Healthcare products Regulatory Agency (MHRA). Both forms are indicated for the short-term treatment of jet-lag in adults.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Commercial Medicines business has signed an exclusive agreement with Accord Healthcare (‘Accord’) to supply and distribute Clinigen’s speciality medicines, Cardioxane® and Savene® in Poland.
Ghent, Belgium – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication.
Cambridge, UK - Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019. CEO Dr Mike Romanos, CSO Dr Trevor Lawley and Head of Bioinformatics Dr Simon Harris will be presenting on commercial and scientific advances and opportunities in the fast-moving microbiome space.
Cambridge, UK - A new set of statistically significant overall survival (OS) data unveiled at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract# LBA1008), and published in The New England Journal of Medicine, are being heralded as a major breakthrough for pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer premenopausal women with advanced breast cancer.
Pleasanton, CA and Tokyo, Japan - Astex Pharmaceuticals, Inc. a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASCERTAIN phase 3 study evaluating cedazuridine and decitabine fixed-dose combination (ASTX727) vs decitabine IV in adults with intermediate and high-risk MDS or CMML.
SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced positive data from the ongoing patients in the Phase Ib study of its HER-Vaxx cancer vaccine was presented at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago Illinois, USA 31 May to 3 June 2019.
Accrington, UK – National Care Group (“NCG”), a leading provider of support services, announces the acquisition of the business and assets of the Integra Group (“Integra”). Financial details of the deal were not disclosed.
SYDNEY, Australia – Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board’s growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).